Medical Health & Life Science Research News

Sarcopenia pipeline therapeutics development market review H2 2017 examined in new market research report

Sarcopenia Pipeline Review H2 2017 provides Sarcopenia drugs profile in pipeline and therapeutics product development by major pharmaceutical companies. Companies involved in Sarcopenia Drugs Therapeutics Development Analyzed in report are Amgen Inc, Biophytis SAS, GlaxoSmithKline Plc, Immusoft Corp, MYOS RENS Technology Inc, Neurotune AG, Novartis AG, Regeneron Pharmaceuticals Inc, Sumitomo Dainippon Pharma Co Ltd and Teijin Pharma Ltd.

- Agency -.

Sarcopenia Pipeline Drugs Therapeutics Market Review H2 2017 latest report on pipeline product development with descriptive Sarcopenia drugs profiles, product, therapeutics development provides comprehensive information on the therapeutics development for Sarcopenia complete with analysis by stage of development Sarcopenia drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Sarcopenia Pipeline guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 7 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule respectively.

- Agency -.

Report encapsulates all the dormant and discontinued pipeline projects also reviews latest news related to pipeline therapeutics for Sarcopenia (Infectious Disease).

Access Report www.reportsnreports.com/contacts/discount.aspx?name=1132651.

Sarcopenia Drugs In Pipeline analysed in report are ARM-210, ATA-842, AVGN-7, bimagrumab, BIO-101, Cell Therapy for Sarcopenia, Gene Therapy to Activate Follistatin for Sarcopenia and Atherosclerosis, NEP-28, NT-1654, Proteins for Musculoskeletal Disorders, Recombinant Protein for Sarcopenia, Small Molecules to Inhibit Furin for Sarcopenia and Cachexia, Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia, TEISARM-2, trevogrumab.

The pipeline guide provides a snapshot of the global therapeutic landscape of Sarcopenia and covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. Report helps you to find and recognize significant and varied types of therapeutics under development for Sarcopenia.

The pipeline guide features descriptive Sarcopenia drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The Sarcopenia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Sarcopenia and features dormant and discontinued projects.

Sarcopenia pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Access This Report at www.reportsnreports.com/purchase.aspx?name=1132651 .

The guide is built using data and information sourced proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Featured News & Press Releases

  1. May 11, 2017: BIOPHYTIS: First patient-in in the United States and opening of 2 clinical centers for the SARA-OBS study on Sarcopenia
  2. May 03, 2017: BIOPHYTIS confirms that Sarconeos modulates the Renin-Angiotensin System and activates muscular metabolism in the SARA-PK clinical trial
  3. Mar 27, 2017: Biophytis opens the first clinical centers in Europe and starts the recruitment of sarcopenic patients for SARA-OBS study
  4. Mar 21, 2017: BIOPHYTIS to present on BIO101 at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Barcelona
  5. Mar 01, 2017: BIOPHYTIS: Full results of SARA-PK study confirm Sarconeos good pharmacokinetic profile in elderly patients

List of Tables:

  1. Number of Products under Development for Sarcopenia, H2 2017
  2. Number of Products under Development by Companies, H2 2017
  3. Number of Products under Development by Universities/Institutes, H2 2017
  4. Products under Development by Companies, H2 2017
  5. Products under Development by Universities/Institutes, H2 2017
  6. Number of Products by Stage and Target, H2 2017
  7. Number of Products by Stage and Mechanism of Action, H2 2017
  8. Number of Products by Stage and Route of Administration, H2 2017
  9. Number of Products by Stage and Molecule Type, H2 2017
  10. Sarcopenia - Pipeline by Amgen Inc, H2 2017
  11. Sarcopenia - Pipeline by Biophytis SAS, H2 2017
  12. Sarcopenia - Pipeline by GlaxoSmithKline Plc, H2 2017
  13. Sarcopenia - Pipeline by Immusoft Corp, H2 2017
  14. Sarcopenia - Pipeline by MYOS RENS Technology Inc, H2 2017
  15. Sarcopenia - Pipeline by Neurotune AG, H2 2017
  16. Sarcopenia - Pipeline by Novartis AG, H2 2017
  17. Sarcopenia - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
  18. Sarcopenia - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017
  19. Sarcopenia - Pipeline by Teijin Pharma Ltd, H2 2017
  20. Sarcopenia - Dormant Projects, H2 2017
  21. Sarcopenia - Discontinued Products, H2 2017

News From

ReportsnReports - Industry Trends & ForecastsReportsnReports
Category: Market Research Publishers and RetailersCompany profile: ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision-making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets.